Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5)
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: Aim: Use of the glucagon‐like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist‐to‐hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods: In the multicentre, double‐blind, placebo‐controlled MDI‐liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist‐to‐hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results: Baseline‐adjusted mean weight loss was 3.8 ± 2.9 kg greater in liraglutide than placebo‐treated individuals (p < 0.0001). Waist circumference was reduced by 2.9 ± 4.3 cm and 0.2 ± 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline‐adjusted mean difference: 2.6 ± 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 ± 1.7 cm and 0.0 ± 1.8 cm (baseline‐adjusted mean difference: 1.1 ± 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline‐adjusted mean difference between treatment groups: 2.8 ± 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist‐to‐hip ratio (baseline‐adjusted mean difference: 0.0 ± 0.04 cm, p = 0.51) or adiponectin levels (baseline‐adjusted mean difference: 0.8 ± 3.3 mg L−1, p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions: In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long‐term hyperglycaemia but did not affect adiponectin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660 · cited 1×
“It is also known that adiponectin levels are lower in individuals with obesity, T2D and insulin resistance (24).”
BackgroundApproved IFCC reference method for the measurement of HbA1c in human blood
Jeppsson, J.-O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., Miedema, K., Mosca, A., Mauri, P., Paroni, R., et al. (2002) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2002.016 · Cited by 655
Body fat distribution, insulin resistance, and metabolic diseases
Björntorp, P. (1997) · Nutrition · doi:10.1016/s0899-9007(97)00191-3 · Cited by 470
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 1×
“(and in particular abdominal obesity) may be due to appetite suppression and lower food intake as well as increased energy expenditure (20,21).”
BackgroundPotts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163
Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
Self-citationSuzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H., Tanaka, E., Kuriyama, Y., Miyatake, H., Abe, M., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8961 · Cited by 61
Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
Wang, A., Li, T., An, P., Yan, W., Zheng, H., Wang, B., & Mu, Y. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169469 · Cited by 58 · cited 1×
“Animal models have shown both liraglutide and other GLP-1-receptor agonists to be associated with increased adiponectin levels (25,26), while there are few data from clinical studies (27–29).”
BackgroundSun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Decara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Takeshita, Y., Takamura, T., Kita, Y., Otoda, T., Kato, K., Wakakuri, H., Yamada, M., Misu, H., Matsushima, Y., Kaneko, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12269 · Cited by 35
Research works printed but not linked: 16
- International Diabetes Federation, 2017, IDF Diabetes Atlas
- 10.1007/s00125-012-2534-0 · DOI · Paper page
- 10.2337/dc14-2441 · DOI · Paper page
- 10.2337/dci18-0033 · DOI · Paper page
- 10.1136/bmjdrc-2017-000464 · DOI · Paper page
- Haluzik M, 2005, Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance, Curr Opin Investig Drugs, 6, 988
- Esfahani M, 2015, Adiponectin: an adipokine with protective features against metabolic syndrome, Iran J Basic Med Sci, 18, 430
- 10.1016/j.pcd.2014.07.010 · DOI
- 10.2146/ajhp150990 · DOI · Paper page
- 10.1007/s40265-015-0408-8 · DOI
- Rondanelli M, 2016, Twenty‐four‐week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer Adherence, 10, 407
- 10.1590/S0004-27302007000600013 · DOI
- 10.1016/j.metabol.2010.04.019 · DOI
- 10.2119/molmed.2011.00051 · DOI · Paper page
- 10.1016/j.diabres.2015.05.051 · DOI
- LindM.Glycaemic control: evaluation of HbA1c as a risk factor and the effect of modern insulins in clinical practicehttp://hdl.handle.net/2077/19641 Accessed May 25 2018.
Cited by
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
“They comprised 6749 patients (inflammation evaluated in 6560, oxidative stress in 701 patients), included a median (IQR) study population of 60 (33-122) participants, and had a median (IQR) follow-up of 6 months (84-182 days).”
BackgroundRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Moon, S., Lee, J., Chung, H. S., Kim, Y. J., Yu, J. M., Yu, S. H., & Oh, C.-M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.934 · Cited by 38
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Metadata
- Authors
- Ahmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Ahrén, B., Dahlqvist, S., Gustafsson, T., Tuomilehto, J., Hirsch, I. B., & Lind, M.
- Venue
- Obesity Science & Practice
- Publisher
- Wiley
- Published
- 2019-03-18
- Volume
- 5
- Issue
- 2
- Pages
- 130-140
- ISSN
- 2055-2238 (ISSN-L)
- OpenAlex
- W2906141776
- Cited by
- 14
- References
- 13
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.